GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Intrinsic Value: Projected FCF
中文

Progyny (Progyny) Intrinsic Value: Projected FCF

: $0.00 (As of Today)
View and export this data going back to 2019. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-23), Progyny's Intrinsic Value: Projected FCF is $0.00. The stock price of Progyny is $32.675. Therefore, Progyny's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Progyny's Intrinsic Value: Projected FCF or its related term are showing as below:

PGNY's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.28
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Progyny Intrinsic Value: Projected FCF Historical Data

The historical data trend for Progyny's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Progyny Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Health Information Services subindustry, Progyny's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progyny Price-to-Projected-FCF Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Progyny's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Progyny's Price-to-Projected-FCF falls into.



Progyny Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Progyny  (NAS:PGNY) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Progyny's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=32.675/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progyny Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Progyny's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Progyny (Progyny) Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Executives
David J Schlanger director, officer: Executive Chairman C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer officer: President 48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston officer: Chief Financial Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski officer: Chief Executive Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz officer: EVP, GC C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean director 185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero officer: EVP, GC and Secretary C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg director
Jennifer Bealer officer: EVP, General Counsel C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton director 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730